Header Logo

Connection

Udho Thadani to Humans

Back to Details
This is a "connection" page, showing publications Udho Thadani has written about Humans.
Udho Thadani
Connection Strength
1.265
Humans
  1. Prognostic Value of 6-Minute Walk Distance in Patients Undergoing Percutaneous Coronary Intervention: a Veterans Affairs Prospective Study. Tex Heart Inst J. 2020 02; 47(1):10-14.
    View in: PubMed
    Score: 0.039
  2. Trimetazidine for stable and unstable ischemic heart diseases and for heart failure: Is its routine use justified from available data? Int J Cardiol. 2020 02 01; 300:45-46.
    View in: PubMed
    Score: 0.038
  3. Trans fatty acids linked to myocardial infarction and stroke: What is the evidence? Trends Cardiovasc Med. 2019 07; 29(5):306-310.
    View in: PubMed
    Score: 0.036
  4. Editorial commentary: Treatment of refractory angina: An ongoing challenge. Trends Cardiovasc Med. 2018 04; 28(3):229-230.
    View in: PubMed
    Score: 0.034
  5. Inappropriate sinus tachycardia-symptom and heart rate reduction with ivabradine: A pooled analysis of prospective studies. Heart Rhythm. 2018 02; 15(2):240-247.
    View in: PubMed
    Score: 0.034
  6. Routine invasive strategies compared with conservative strategies do not lower the all-cause mortality in patients with non-ST elevation myocardial infarction and unstable angina. Evid Based Med. 2017 10; 22(5):190.
    View in: PubMed
    Score: 0.033
  7. Drug Therapy for Stable Angina Pectoris. Drugs. 2017 Mar; 77(3):265-284.
    View in: PubMed
    Score: 0.032
  8. The risk of cardiovascular side effects with anti-anginal drugs. Expert Opin Drug Saf. 2016 Dec; 15(12):1609-1623.
    View in: PubMed
    Score: 0.031
  9. Management of Stable Angina - Current Guidelines: A Critical Appraisal. Cardiovasc Drugs Ther. 2016 Aug; 30(4):419-426.
    View in: PubMed
    Score: 0.031
  10. Invasive strategy in acute coronary syndrome. Lancet. 2016 Jun 18; 387(10037):2503-4.
    View in: PubMed
    Score: 0.031
  11. Percutaneous coronary interventions in the elderly improve quality of life: evidence far from certain. Cardiology. 2014; 129(1):44-5.
    View in: PubMed
    Score: 0.027
  12. Challenges with nitrate therapy and nitrate tolerance: prevalence, prevention, and clinical relevance. Am J Cardiovasc Drugs. 2014 Aug; 14(4):287-301.
    View in: PubMed
    Score: 0.027
  13. Pigment epithelial-derived factor and acute coronary syndrome: a novel protective biomarker but not for routine clinical use at present. Cardiology. 2014; 127(1):28-30.
    View in: PubMed
    Score: 0.026
  14. Retroperitoneal hemorrhage after cardiac catheterization and percutaneous coronary interventions. Cardiology. 2013; 126(1):24-6.
    View in: PubMed
    Score: 0.025
  15. Is risk factor control and guideline-based medical therapy optimal in patients with nonobstructive coronary artery disease? A Veterans Affairs study. Am J Med Sci. 2013 May; 345(5):339-42.
    View in: PubMed
    Score: 0.025
  16. Obesity, brain natriuretic peptide levels and mortality in patients hospitalized with heart failure and preserved left ventricular systolic function. Am J Med Sci. 2013 Mar; 345(3):211-7.
    View in: PubMed
    Score: 0.024
  17. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal. Expert Opin Pharmacother. 2012 Dec; 13(17):2555-63.
    View in: PubMed
    Score: 0.024
  18. Osteoprotegerin and ST segment myocardial infarction: a novel risk marker but not for routine use at present. Cardiology. 2012; 123(2):91-3.
    View in: PubMed
    Score: 0.024
  19. The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis. J Cardiovasc Electrophysiol. 2012 Feb; 23(2):163-8.
    View in: PubMed
    Score: 0.022
  20. Exercise performance, physical activity, and health-related quality of life in participants with stable angina. Angiology. 2011 Aug; 62(6):461-6.
    View in: PubMed
    Score: 0.021
  21. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Am J Med Sci. 2011 Jan; 341(1):1-9.
    View in: PubMed
    Score: 0.021
  22. Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients. Am J Cardiol. 2009 Jun 15; 103(12):1687-93.
    View in: PubMed
    Score: 0.019
  23. Treatment with statins in high-risk patients: relevance of time to titration of dose and adverse outcomes. Am J Cardiovasc Drugs. 2009; 9(3):211-2; author reply 212.
    View in: PubMed
    Score: 0.018
  24. Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure. Drugs Today (Barc). 2008 Dec; 44(12):925-37.
    View in: PubMed
    Score: 0.018
  25. Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction. Expert Opin Drug Saf. 2007 Jul; 6(4):385-96.
    View in: PubMed
    Score: 0.016
  26. Side effects of using nitrates to treat angina. Expert Opin Drug Saf. 2006 Sep; 5(5):667-74.
    View in: PubMed
    Score: 0.016
  27. Therapy of stable angina pectoris: the uncomplicated patient. Circulation. 2005 Oct 11; 112(15):e255-9.
    View in: PubMed
    Score: 0.015
  28. Modified-release formulation of trimetazidine for exceptional control of angina pectoris: fact or fiction. Am J Cardiovasc Drugs. 2005; 5(5):331-4.
    View in: PubMed
    Score: 0.014
  29. Current medical management of chronic stable angina. J Cardiovasc Pharmacol Ther. 2004 Sep; 9 Suppl 1:S11-29; quiz S98-9.
    View in: PubMed
    Score: 0.014
  30. Prevention of nitrate tolerance with angiotensin II receptor type 1 blocker in patients with stable angina: yet another failed strategy to prevent tolerance. Cardiovasc Drugs Ther. 2004 Sep; 18(5):339-42.
    View in: PubMed
    Score: 0.014
  31. Recurrent and refractory angina following revascularization procedures in patients with stable angina pectoris. Coron Artery Dis. 2004 May; 15 Suppl 1:S1-4.
    View in: PubMed
    Score: 0.013
  32. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 04; 40(11):2006-12.
    View in: PubMed
    Score: 0.012
  33. Selective L-type, T-type, and nonspecific calcium-channel blockers for stable angina pectoris. Am Heart J. 2002 Jul; 144(1):8-10.
    View in: PubMed
    Score: 0.012
  34. Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. Am J Cardiol. 2021 05 01; 146:36-47.
    View in: PubMed
    Score: 0.011
  35. Rapid-release and coat-core formulations of nisoldipine in treatment of hypertension, angina, and heart failure. Heart Dis. 1999 Nov-Dec; 1(5):279-88.
    View in: PubMed
    Score: 0.010
  36. Treatment of stable angina. Curr Opin Cardiol. 1999 Jul; 14(4):349-58.
    View in: PubMed
    Score: 0.009
  37. Choosing the most appropriate treatment for stable angina. Safety considerations. Drug Saf. 1998 Jul; 19(1):23-44.
    View in: PubMed
    Score: 0.009
  38. FDA Panel report: January 1998. Circulation. 1998 Jun 16; 97(23):2295-6.
    View in: PubMed
    Score: 0.009
  39. Severe symptomatic sinus bradycardia associated with mesalamine use. Am J Gastroenterol. 1998 Mar; 93(3):470-1.
    View in: PubMed
    Score: 0.009
  40. Lack of arrhythmogenicity with ST-segment elevation during high-dose of dobutamine atropine stress in patients with documented or suspected coronary artery disease. Am J Cardiol. 1997 Aug 01; 80(3):341-3.
    View in: PubMed
    Score: 0.008
  41. Management of patients with chronic stable angina at low risk for serious cardiac events. Am J Cardiol. 1997 Jun 26; 79(12B):24-30.
    View in: PubMed
    Score: 0.008
  42. Oral nitrates: more than symptomatic therapy in coronary artery disease? Cardiovasc Drugs Ther. 1997 May; 11 Suppl 1:213-8.
    View in: PubMed
    Score: 0.008
  43. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris. Am J Cardiol. 1997 Apr 15; 79(8):1025-30.
    View in: PubMed
    Score: 0.008
  44. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovasc Drugs Ther. 1997 Jan; 10(6):735-42.
    View in: PubMed
    Score: 0.008
  45. Secondary preventive potential of nitrates in ischaemic heart disease. Eur Heart J. 1996 Dec; 17 Suppl F:30-6.
    View in: PubMed
    Score: 0.008
  46. Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. JACC Heart Fail. 2016 05; 4(5):348-56.
    View in: PubMed
    Score: 0.007
  47. Hypertension and cardiovascular disease risk in women. Med Sci Sports Exerc. 1996 Jan; 28(1):7-8.
    View in: PubMed
    Score: 0.007
  48. Management Strategies and Outcomes of ST-Segment Elevation Myocardial Infarction Patients Transferred After Receiving Fibrinolytic Therapy in the United States. Clin Cardiol. 2016 Jan; 39(1):9-18.
    View in: PubMed
    Score: 0.007
  49. Chronic stable angina pectoris. Strategies for effective drug therapy. Postgrad Med. 1995 Dec; 98(6):175-6, 179-83, 187-8.
    View in: PubMed
    Score: 0.007
  50. Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther. 1994 Aug; 8(4):611-23.
    View in: PubMed
    Score: 0.007
  51. Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther. 1994 Aug; 8(4):625-33.
    View in: PubMed
    Score: 0.007
  52. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group. Circulation. 1994 Aug; 90(2):726-34.
    View in: PubMed
    Score: 0.007
  53. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST) Circulation. 1994 Aug; 90(2):762-8.
    View in: PubMed
    Score: 0.007
  54. Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Diltiazem CD Study Group. Am J Cardiol. 1994 Jul 01; 74(1):9-17.
    View in: PubMed
    Score: 0.007
  55. Duration of effects of isradipine during twice daily therapy in angina pectoris. Cardiovasc Drugs Ther. 1994 Apr; 8(2):199-210.
    View in: PubMed
    Score: 0.007
  56. Mononitrates: defining the ideal long-acting nitrate. Clin Ther. 1994 Mar-Apr; 16(2):130-9; discussion 129.
    View in: PubMed
    Score: 0.007
  57. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann Intern Med. 1994 Mar 01; 120(5):353-9.
    View in: PubMed
    Score: 0.007
  58. Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction. J Am Heart Assoc. 2013 Aug 21; 2(4):e000214.
    View in: PubMed
    Score: 0.006
  59. Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function. Clin Cardiol. 2013 Oct; 36(10):611-20.
    View in: PubMed
    Score: 0.006
  60. Nitrate therapy and the development of tolerance. Arch Fam Med. 1993 Aug; 2(8):880-5.
    View in: PubMed
    Score: 0.006
  61. Efficacy of isosorbide mononitrate in angina pectoris. Am J Cardiol. 1992 Nov 27; 70(17):67G-71G.
    View in: PubMed
    Score: 0.006
  62. Role of nitrates in angina pectoris. Am J Cardiol. 1992 Sep 24; 70(8):43B-53B.
    View in: PubMed
    Score: 0.006
  63. Effects of 8:00 a.m. and 2:00 p.m. doses of isosorbide-5-mononitrate during twice-daily therapy in stable angina pectoris. Am J Cardiol. 1992 Aug 01; 70(3):286-92.
    View in: PubMed
    Score: 0.006
  64. Nitrates as an integral part of optimal medical therapy and cardiac rehabilitation for stable angina: review of current concepts and therapeutics. Clin Cardiol. 2012 May; 35(5):263-71.
    View in: PubMed
    Score: 0.006
  65. Nitrate tolerance. How to prevent it or minimize its effect. Postgrad Med. 1992 Apr; 91(5):307-12, 315-8.
    View in: PubMed
    Score: 0.006
  66. Successful surgical repair of a ruptured aneurysm of the sinus of Valsalva in early pregnancy. Ann Intern Med. 1991 Dec 01; 115(11):880-2.
    View in: PubMed
    Score: 0.006
  67. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris. Circulation. 1991 Dec; 84(6):2398-408.
    View in: PubMed
    Score: 0.006
  68. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation. 2011 Oct 25; 124(17):1811-8.
    View in: PubMed
    Score: 0.006
  69. Beta-adrenergic blockers and intermittent claudication. Time for reappraisal. Arch Intern Med. 1991 Sep; 151(9):1705-7.
    View in: PubMed
    Score: 0.005
  70. Medical therapy of stable angina pectoris. Cardiol Clin. 1991 Feb; 9(1):73-87.
    View in: PubMed
    Score: 0.005
  71. A multicenter comparison of isradipine and prazosin for treatment of essential hypertension. Cardiovasc Drugs Ther. 1990 Apr; 4(2):413-7.
    View in: PubMed
    Score: 0.005
  72. Amlodipine: a once-daily calcium antagonist in the treatment of angina pectoris--a parallel dose-response, placebo-controlled study. The Amlodipine Study Group. Am Heart J. 1989 Nov; 118(5 Pt 2):1135.
    View in: PubMed
    Score: 0.005
  73. Safety of symptom-limited cardiopulmonary exercise testing in patients with chronic heart failure due to severe left ventricular systolic dysfunction. Am Heart J. 2009 Oct; 158(4 Suppl):S72-7.
    View in: PubMed
    Score: 0.005
  74. Nitrate therapy for myocardial ischemic syndrome: current perspectives including tolerance. Curr Probl Cardiol. 1988 Nov; 13(11):723-84.
    View in: PubMed
    Score: 0.005
  75. Relationship of pharmacokinetic and pharmacodynamic properties of the organic nitrates. Clin Pharmacokinet. 1988 Jul; 15(1):32-43.
    View in: PubMed
    Score: 0.004
  76. Long-term bepridil monotherapy for angina pectoris. Am J Cardiol. 1988 Jun 01; 61(15):1210-3.
    View in: PubMed
    Score: 0.004
  77. Amlodipine--a once-daily calcium antagonist in the treatment of angina pectoris: a parallel dose-response placebo-controlled study. J Cardiovasc Pharmacol. 1988; 12 Suppl 7:S114.
    View in: PubMed
    Score: 0.004
  78. Noninvasive evaluation of aortic stenosis severity utilizing Doppler ultrasound and electrical bioimpedance. J Am Coll Cardiol. 1988 Jan; 11(1):66-71.
    View in: PubMed
    Score: 0.004
  79. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2008 Feb; 31(2):353-60.
    View in: PubMed
    Score: 0.004
  80. Usefulness of twice-daily isosorbide-5-mononitrate in preventing development of tolerance in angina pectoris. Am J Cardiol. 1987 Sep 01; 60(7):477-82.
    View in: PubMed
    Score: 0.004
  81. Nitrate therapy: continuous or pulse dosing. Ration Drug Ther. 1987 Jul; 21(7):1-6.
    View in: PubMed
    Score: 0.004
  82. Isosorbide-5-mononitrate in angina pectoris: plasma concentrations and duration of effects after acute therapy. Clin Pharmacol Ther. 1987 Jul; 42(1):58-65.
    View in: PubMed
    Score: 0.004
  83. Duration of effects and tolerance of slow-release isosorbide-5-mononitrate for angina pectoris. Am J Cardiol. 1987 Apr 01; 59(8):756-62.
    View in: PubMed
    Score: 0.004
  84. The effectiveness of transcutaneous nitrate preparations for angina pectoris. Int J Cardiol. 1987 Jan; 14(1):9-14.
    View in: PubMed
    Score: 0.004
  85. Clinically silent atrial septal defects with evidence for cerebral embolization. Ann Intern Med. 1986 Nov; 105(5):695-7.
    View in: PubMed
    Score: 0.004
  86. Rupture of abdominal aortic aneurysm during exercise. Gated blood pool studies. Am J Med. 1986 Nov; 81(5):887-9.
    View in: PubMed
    Score: 0.004
  87. Transdermal nitroglycerin patches in angina pectoris. Dose titration, duration of effect, and rapid tolerance. Ann Intern Med. 1986 Oct; 105(4):485-92.
    View in: PubMed
    Score: 0.004
  88. Quantification of aortic regurgitation utilizing continuous wave Doppler ultrasound. J Am Coll Cardiol. 1986 Sep; 8(3):592-9.
    View in: PubMed
    Score: 0.004
  89. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006 Sep; 48(3):374-84.
    View in: PubMed
    Score: 0.004
  90. Improvement in angina pectoris with alpha adrenoceptor blockade. Br Heart J. 1986 Feb; 55(2):219-20.
    View in: PubMed
    Score: 0.004
  91. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol. 2005 Nov 15; 46(10):1803-11.
    View in: PubMed
    Score: 0.004
  92. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005 Jun 27; 165(12):1401-9.
    View in: PubMed
    Score: 0.004
  93. Comparative efficacy of 200, 300 and 400 mg of bepridil for chronic stable angina pectoris. Am J Cardiol. 1985 Mar 15; 55(7):36C-42C.
    View in: PubMed
    Score: 0.004
  94. Assessment of "optimal" beta blockade in treating patients with angina pectoris. Acta Med Scand Suppl. 1985; 694:178-87.
    View in: PubMed
    Score: 0.003
  95. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris. Z Kardiol. 1985; 74 Suppl 4:21-4.
    View in: PubMed
    Score: 0.003
  96. Nitrates for angina pectoris. A critical review of therapeutic efficacy and tolerance. Herz. 1984 Jun; 9(3):123-36.
    View in: PubMed
    Score: 0.003
  97. Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol. 2003 Dec 17; 42(12):2049-59.
    View in: PubMed
    Score: 0.003
  98. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J. 2003 Dec; 24(24):2206-12.
    View in: PubMed
    Score: 0.003
  99. Beta blockers in hypertension. Am J Cardiol. 1983 Nov 10; 52(9):10D-15D.
    View in: PubMed
    Score: 0.003
  100. Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. Am J Cardiol. 2003 Feb 01; 91(3):274-9.
    View in: PubMed
    Score: 0.003
  101. Interaction of indomethacin and nitroglycerin on hemodynamics and exercise tolerance in patients with angina pectoris. Z Kardiol. 1983; 72 Suppl 3:35-9.
    View in: PubMed
    Score: 0.003
  102. Influence of attenuation on radionuclide stroke volume determinations. J Nucl Med. 1982 Sep; 23(9):781-5.
    View in: PubMed
    Score: 0.003
  103. Beta adrenergic blocking agents for exertional angina pectoris. Herz. 1982 Jun; 7(3):179-87.
    View in: PubMed
    Score: 0.003
  104. Usefulness of clinical information to distinguish patients with normal from those with low ejection fractions in heart failure. Am J Cardiol. 2002 May 15; 89(10):1218-21.
    View in: PubMed
    Score: 0.003
  105. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy. Am J Cardiol. 1982 Feb 01; 49(2):411-9.
    View in: PubMed
    Score: 0.003
  106. Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction. Clin Pharmacokinet. 2002; 41(6):445-52.
    View in: PubMed
    Score: 0.003
  107. Hemodynamic effects of disopyramide at rest and during exercise in normal subjects. Cathet Cardiovasc Diagn. 1981; 7(1):27-34.
    View in: PubMed
    Score: 0.003
  108. Oral isosorbide dinitrate in the treatment of angina pectoris. Dose-response relationship and duration of action during acute therapy. Circulation. 1980 Sep; 62(3):491-502.
    View in: PubMed
    Score: 0.003
  109. Propranolol in angina pectoris: comparison of therapy given two and four times daily. Am J Cardiol. 1980 Jul; 46(1):117-23.
    View in: PubMed
    Score: 0.003
  110. Are the clinical and hemodynamic events during exercise stress testing in invasive studies in patients with angina pectoris reproducible? Circulation. 1980 Apr; 61(4):744-50.
    View in: PubMed
    Score: 0.002
  111. Tolerance to the circulatory effects of oral isosorbide dinitrate. Rate of development and cross-tolerance to glyceryl trinitrate. Circulation. 1980 Mar; 61(3):526-35.
    View in: PubMed
    Score: 0.002
  112. Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris. Am J Med. 1980 Feb; 68(2):243-50.
    View in: PubMed
    Score: 0.002
  113. Effects of low and high glucose in a glucose-insulin-potassium infusion on hemodynamics and exercise tolerance in patients with angina pectoris. Circulation. 1980 Feb; 61(2):266-76.
    View in: PubMed
    Score: 0.002
  114. Reproducibility of clinical and hemodynamic parameters during pacing stress testing in patients with angina pectoris. Circulation. 1979 Nov; 60(5):1036-44.
    View in: PubMed
    Score: 0.002
  115. Cardiac performance at rest and during exercise in normal subjects. Bull Eur Physiopathol Respir. 1979 Sep-Oct; 15(5):935-49.
    View in: PubMed
    Score: 0.002
  116. Clinical, hemodynamic and metabolic responses during pacing in the supine and sitting postures in patients with angina pectoris. Am J Cardiol. 1979 Aug; 44(2):249-56.
    View in: PubMed
    Score: 0.002
  117. Propranolol in angina pectoris: duration of improved exercise tolerance and circulatory effects after acute oral administration. Am J Cardiol. 1979 Jul; 44(1):118-25.
    View in: PubMed
    Score: 0.002
  118. Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris. N Engl J Med. 1979 Apr 05; 300(14):750-5.
    View in: PubMed
    Score: 0.002
  119. Propranolol in the treatment of angina pectoris. Comparison of duration of action in acute and sustained oral therapy. Circulation. 1979 Mar; 59(3):571-9.
    View in: PubMed
    Score: 0.002
  120. Effects of glucose-insulin-potassium infusion on the angina response during treadmill exercise. Cardiology. 1979; 64(6):333-49.
    View in: PubMed
    Score: 0.002
  121. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation. 1998 Nov 17; 98(20):2117-25.
    View in: PubMed
    Score: 0.002
  122. Influence of glyceryl trinitrate during supine and upright exercise in patients with angina pectoris. Br Heart J. 1978 Nov; 40(11):1229-36.
    View in: PubMed
    Score: 0.002
  123. Hemodynamics at rest and during supine and sitting bicycle exercise in normal subjects. Am J Cardiol. 1978 Jan; 41(1):52-9.
    View in: PubMed
    Score: 0.002
  124. Submitral annular left ventricular aneurysm--unusual echocardiographic and angiographic features. Cathet Cardiovasc Diagn. 1978; 4(2):163-74.
    View in: PubMed
    Score: 0.002
  125. Effect of morning versus evening dosing of diltiazem on myocardial ischemia detected by ambulatory electrocardiographic monitoring in chronic stable angina pectoris. Dilacor XR Ambulatory Ischemia Study Group. Am J Cardiol. 1997 Aug 15; 80(4):421-5.
    View in: PubMed
    Score: 0.002
  126. Hemodynamics at rest and during supine and sitting bicycle exercise in patients with coronary artery disease. Am J Cardiol. 1977 May 26; 39(6):776-83.
    View in: PubMed
    Score: 0.002
  127. Effects of zatebradine (ULFS 49 CL), a sinus node inhibitor, on heart rate and exercise duration in chronic stable angina pectoris. Zatebradine Investigators. Am J Cardiol. 1997 May 15; 79(10):1401-5.
    View in: PubMed
    Score: 0.002
  128. Comparative anti-hypertensive effectiveness of beta-adrenoreceptor antagonists with different pharmacological properties: dose-response studies during acute and chronic administration. Clin Sci Mol Med Suppl. 1976 Dec; 3:541s-544s.
    View in: PubMed
    Score: 0.002
  129. Oxprenolol in angina pectoris [proceedings]. Br J Pharmacol. 1976 Nov; 58(3):412P.
    View in: PubMed
    Score: 0.002
  130. Proceedings: Comparison of antihypertensive effectiveness of beta-adrenoceptor antagonists with different pharmacological properties. Br Heart J. 1976 Mar; 38(3):313.
    View in: PubMed
    Score: 0.002
  131. Cardiac tamponade, constrictive pericarditis and pericardial resection in rheumatoid arthritis. Medicine (Baltimore). 1975 May; 54(3):261-70.
    View in: PubMed
    Score: 0.002
  132. Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. Am Heart J. 1995 Mar; 129(3):527-35.
    View in: PubMed
    Score: 0.002
  133. Congenital intrapericardial aneurysms of the left atrium. Thorax. 1975 Feb; 30(1):102-9.
    View in: PubMed
    Score: 0.002
  134. Massive splenomegaly, pancytopenia and haemolytic anaemia in sarcoidosis. Acta Haematol. 1975; 53(4):230-40.
    View in: PubMed
    Score: 0.002
  135. Pulmonary veno-occlusive disease. Q J Med. 1975 Jan; 44(173):133-59.
    View in: PubMed
    Score: 0.002
  136. Conversion from immediate-release to extended-release diltiazem in angina pectoris. Clin Cardiol. 1994 Sep; 17(9):484-8.
    View in: PubMed
    Score: 0.002
  137. Rheumatoid lung disease with pulmonary fibrosis necrobiotic nodules and pleural effusion. Br J Dis Chest. 1973 Apr; 67(2):146-52.
    View in: PubMed
    Score: 0.002
  138. Myocardial infarct artery patency and reocclusion rates after treatment with duteplase at the dose used in the International Study of Infarct Survival-3. Burroughs Wellcome Study Group. Am J Cardiol. 1993 Feb 15; 71(5):386-92.
    View in: PubMed
    Score: 0.002
  139. Comparison of adrenergic beta-receptor antagonists in angina pectoris. Br Med J. 1973 Jan 20; 1(5846):138-42.
    View in: PubMed
    Score: 0.002
  140. Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction. Am J Cardiol. 1992 May 01; 69(14):1120-7.
    View in: PubMed
    Score: 0.001
  141. Profunda femoral arteriovenous fistula after percutaneous arterial and venous catheterization. Br Heart J. 1971 Sep; 33(5):803-5.
    View in: PubMed
    Score: 0.001
  142. Pericarditis after acute myocardial infarction. Br Med J. 1971 Apr 17; 2(5754):135-7.
    View in: PubMed
    Score: 0.001
  143. Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia. Psychosom Med. 1988 Jul-Aug; 50(4):381-93.
    View in: PubMed
    Score: 0.001
  144. Effects of 1-epinephrine on hemodynamics and cardiac function in coronary disease: dose-response studies. Clin Pharmacol Ther. 1988 Mar; 43(3):308-16.
    View in: PubMed
    Score: 0.001
  145. Doppler echocardiographic profiles in obstructive right and left atrial myxomas. J Am Coll Cardiol. 1987 Mar; 9(3):701-3.
    View in: PubMed
    Score: 0.001
  146. Atenolol for ventricular ectopy: a dose-response study. Clin Pharmacol Ther. 1987 Jan; 41(1):118-23.
    View in: PubMed
    Score: 0.001
  147. Kinetics of isosorbide dinitrate and relationships to pharmacological effects. Br J Clin Pharmacol. 1981 Jun; 11(6):579-89.
    View in: PubMed
    Score: 0.001
  148. Slow release oxprenolol in angina pectoris: study comparing oxprenolol, once daily, with propranolol, four times daily. Am J Cardiol. 1981 May; 47(5):1123-7.
    View in: PubMed
    Score: 0.001
  149. Subaortic annular left ventricular aneurysm: an unusual cause of aortic regurgitation. Cathet Cardiovasc Diagn. 1980; 6(3):285-91.
    View in: PubMed
    Score: 0.001
  150. Slow release oxprenolol in angina pectoris [proceedings]. Br J Clin Pharmacol. 1977 Jun; 4(3):387P.
    View in: PubMed
    Score: 0.001
  151. Comparison of antihypertensive activity of beta-blocking drugs during chronic treatment. Br Med J. 1976 Jul 03; 2(6026):7-9.
    View in: PubMed
    Score: 0.000
  152. Aortic valve incompetence and replacement in rheumatoid arthritis. Ann Rheum Dis. 1975 Aug; 34(4):312-20.
    View in: PubMed
    Score: 0.000
  153. A comparative study of the activity of beta-adrenoceptor antagonists in man. Int J Clin Pharmacol Biopharm. 1975 Jul; 12(1-2):305-6.
    View in: PubMed
    Score: 0.000
  154. Proceedings: Left ventricular pressure-volume changes during exercise-induced pain in patients with angina pectoris. Br Heart J. 1974 Oct; 36(10):1038.
    View in: PubMed
    Score: 0.000
  155. Cardiovascular effects of weight reduction in obese patients with angina pectoris. Br Heart J. 1974 Sep; 36(9):854-8.
    View in: PubMed
    Score: 0.000
  156. Plasma cortisol, urinary 17-hydroxycorticoids, and urinary vanilyl mandelic acid after acute myocardial infarction. Br Heart J. 1972 Oct; 34(10):992-7.
    View in: PubMed
    Score: 0.000
  157. Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double-blind trial. Br Med J. 1971 Sep 18; 3(5776):668-70.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.